The Cutaneous Lymphoma International Prognostic Index (CLIPI) incorporates clinical and laboratory parameters to improve risk stratification in advanced mycosis fungoides (MF) and Sézary syndrome (SS).
CLIPI effectively predicts progression-free survival (PFS) and the best objective response (BOR) during follow-up, surpassing the prognostic value of traditional TNMB staging.
Higher CLIPI scores are correlated with increased risks of disease progression and death, and lower odds of favorable treatment response.
Integrating CLIPI into routine clinical practice may optimize treatment decisions and inform clinical trial designs for MF/SS.
